EisenhoferGPacakKMaherER, et al. Pheochromocytoma. Clin Chem2013; 59: 466–472.
2.
LoCYLamKYWatMS, et al. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg2000; 179: 212–215.
3.
OmuraMSaitoJYamaguchiK, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res2004; 27(3): 193–202.
4.
BerglandBE. Pheochromocytoma presenting as shock. Am J Emerg Med1989; 7: 44–48.
5.
WhitelawBCPragueJKMustafaOG, et al. Phaeochromocytoma crisis. Clin Endocrinol (Oxf)2014; 80: 13–22.
6.
SwanHJ. Noradrenaline, adrenaline, and the human circulation. Br Med J1952; 1: 1003–1006.
7.
NappLCKühnCBauersachsJ. ECMO in cardiac arrest and cardiogenic shock. Herz2017; 42: 27–44.
8.
MatteucciMKowalewskiMFinaD, et al. Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review. Perfusion2020; 35 (1S): xx-xx.
9.
ScholtenACiscoRMVriensMR, et al. Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab2013; 98: 581–591.
10.
OstadalPRokytaRKrugerA, et al. Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial. Eur J Heart Fail2017; 19(Suppl. 2): 124–127.
